Literature DB >> 26824470

Dynorphin A analogs for the treatment of chronic neuropathic pain.

Sara M Hall1, Yeon Sun Lee1, Victor J Hruby1.   

Abstract

Chronic pain is one of the most ubiquitous diseases in the world, but treatment is difficult with conventional methods, due to undesirable side effects of treatments and unknown mechanisms of pathological pain states. The endogenous peptide, dynorphin A has long been established as a target for the treatment of pain. Interestingly, this unique peptide has both inhibitory (opioid in nature) and excitatory activities (nonopioid) in the CNS. Both of these effects have been found to play a role in pain and much work has been done to develop therapeutics to enhance the inhibitory effects. Here we will review the dynorphin A compounds that have been designed for the modulation of pain and will discuss where the field stands today.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26824470      PMCID: PMC4976860          DOI: 10.4155/fmc.15.164

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  112 in total

Review 1.  The NMDA receptor complex as a therapeutic target in epilepsy: a review.

Authors:  Mehdi Ghasemi; Steven C Schachter
Journal:  Epilepsy Behav       Date:  2011-11-04       Impact factor: 2.937

2.  Blockade of the glycine modulatory site of NMDA receptors modifies dynorphin-induced behavioral effects.

Authors:  R Bakshi; A I Faden
Journal:  Neurosci Lett       Date:  1990-03-02       Impact factor: 3.046

3.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Dynorphin A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism.

Authors:  Q Tang; R M Lynch; F Porreca; J Lai
Journal:  J Neurophysiol       Date:  2000-05       Impact factor: 2.714

5.  Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network.

Authors:  Pål Klepstad; Stein Kaasa; Nathan Cherny; Geoffrey Hanks; Franco de Conno
Journal:  Palliat Med       Date:  2005-09       Impact factor: 4.762

6.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

7.  Kappa opioid receptor (KOR) and GAD67 immunoreactivity are found in OFF and NEUTRAL cells in the rostral ventromedial medulla.

Authors:  Clayton W Winkler; Sam M Hermes; Charles I Chavkin; Carrie T Drake; Shaun F Morrison; Sue A Aicher
Journal:  J Neurophysiol       Date:  2006-09-27       Impact factor: 2.714

8.  Dynorphin potentiation of [3H]CGP-39653 binding to rat brain membranes.

Authors:  M Dumont; S Lemaire
Journal:  Eur J Pharmacol       Date:  1994-12-12       Impact factor: 4.432

9.  Behavioral effects of dynorphin 1-13 in the mouse and rat: initial observations.

Authors:  J M Walker; R J Katz; H Akil
Journal:  Peptides       Date:  1980       Impact factor: 3.750

10.  Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues.

Authors:  H Yoshino; T Nakazawa; Y Arakawa; T Kaneko; Y Tsuchiya; M Matsunaga; S Araki; M Ikeda; K Yamatsu; S Tachibana
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

View more
  5 in total

1.  Dynorphin participates in interaction between depression and non-erosive reflux disease.

Authors:  Yi Wang; Bingduo Zhou; Shengquan Fang; Shengliang Zhu; Tingting Xu; Makan Dilikumaer; Guanwu Li
Journal:  Esophagus       Date:  2022-10-16       Impact factor: 3.671

Review 2.  Endogenous Opioid Dynorphin Is a Potential Link between Traumatic Brain Injury, Chronic Pain, and Substance Use Disorder.

Authors:  Kaitlin M Best; Marissa M Mojena; Gordon A Barr; Heath D Schmidt; Akiva S Cohen
Journal:  J Neurotrauma       Date:  2022-01       Impact factor: 4.869

3.  Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships.

Authors:  Filippo Erli; Elena Guerrieri; Tanila Ben Haddou; Aquilino Lantero; Michael Mairegger; Helmut Schmidhammer; Mariana Spetea
Journal:  J Med Chem       Date:  2017-08-30       Impact factor: 7.446

4.  Bulleyaconitine A Inhibits Visceral Nociception and Spinal Synaptic Plasticity through Stimulation of Microglial Release of Dynorphin A.

Authors:  Sheng-Nan Huang; Jinbao Wei; Lan-Ting Huang; Pei-Jun Ju; Jinghong Chen; Yong-Xiang Wang
Journal:  Neural Plast       Date:  2020-05-23       Impact factor: 3.599

5.  Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.